NZ599643A - Substituted N-aryl pyridinones as fibrotic inhibitors - Google Patents
Substituted N-aryl pyridinones as fibrotic inhibitorsInfo
- Publication number
- NZ599643A NZ599643A NZ599643A NZ59964308A NZ599643A NZ 599643 A NZ599643 A NZ 599643A NZ 599643 A NZ599643 A NZ 599643A NZ 59964308 A NZ59964308 A NZ 59964308A NZ 599643 A NZ599643 A NZ 599643A
- Authority
- NZ
- New Zealand
- Prior art keywords
- fibrosis
- deuterium
- substituted
- collagen
- fibrotic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94513607P | 2007-06-20 | 2007-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599643A true NZ599643A (en) | 2013-11-29 |
Family
ID=39731521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599643A NZ599643A (en) | 2007-06-20 | 2008-06-20 | Substituted N-aryl pyridinones as fibrotic inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US8383823B2 (enExample) |
| EP (1) | EP2170828B1 (enExample) |
| JP (1) | JP5587184B2 (enExample) |
| KR (2) | KR101767849B1 (enExample) |
| CN (2) | CN104892498A (enExample) |
| AU (1) | AU2008265595B2 (enExample) |
| CA (1) | CA2691379C (enExample) |
| DK (1) | DK2170828T3 (enExample) |
| ES (1) | ES2400026T3 (enExample) |
| HK (1) | HK1214251A1 (enExample) |
| IL (1) | IL202840A (enExample) |
| NZ (1) | NZ599643A (enExample) |
| WO (1) | WO2008157786A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
| KR101767849B1 (ko) | 2007-06-20 | 2017-08-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논 |
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| WO2009035598A1 (en) * | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| US20110313004A1 (en) * | 2008-12-04 | 2011-12-22 | Concert Pharmaceuticals, Inc. | Deuterated pyridinones |
| AU2010248758A1 (en) * | 2009-05-15 | 2011-11-24 | Intermune, Inc. | Methods of treating HIV patients with anti-fibrotics |
| TWI434833B (zh) | 2009-06-03 | 2014-04-21 | Intermune Inc | 用於合成吡非尼酮（ｐｉｒｆｅｎｉｄｏｎｅ）的改良方法 |
| US20110053968A1 (en) * | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
| CN101921225B (zh) * | 2009-06-11 | 2013-04-03 | 北京凯得尔森生物技术有限公司 | 吡啡尼酮类化合物、其制备方法和应用 |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US10092552B2 (en) | 2011-01-31 | 2018-10-09 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US9018232B2 (en) | 2011-03-08 | 2015-04-28 | Auspex Pharmaceuticals, Inc. | Substituted N-aryl pyridinones |
| CA2835438A1 (en) * | 2011-05-25 | 2012-11-29 | Intermune, Inc. | Pirfenidone and anti-fibrotic therapy in selected patients |
| MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| HK1201299A1 (en) | 2011-11-22 | 2015-08-28 | Intermune, Inc. | Methods of diagnosing and treating idiopathic pulmonary fibrosis |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| US12226407B2 (en) | 2012-07-24 | 2025-02-18 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US9402821B2 (en) * | 2012-08-13 | 2016-08-02 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for treatment of cystic fibrosis |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| AU2014243773B2 (en) | 2013-03-13 | 2018-12-13 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
| MX2015012437A (es) * | 2013-03-13 | 2016-04-15 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones, y usos de los mismos. |
| EP4491180A1 (en) | 2014-01-10 | 2025-01-15 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| JP2017503839A (ja) * | 2014-01-24 | 2017-02-02 | オースペックス ファーマシューティカルズ インコーポレイテッド | 置換ｎ−アリールピリジノン |
| EA201691582A1 (ru) | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| US20150284327A1 (en) * | 2014-04-04 | 2015-10-08 | Auspex Pharmaceuticals, Inc. | Oxindole inhibitors of tyrosine kinase |
| WO2015171345A1 (en) * | 2014-04-30 | 2015-11-12 | Auspex Pharmaceuticals, Inc. | N-aryl pyridinones modulators of fibrosis and/or collagen infiltration |
| US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| KR102465027B1 (ko) * | 2015-02-10 | 2022-11-09 | 액섬 테라퓨틱스, 인크. | 멜록시캄을 포함하는 약학 조성물 |
| US11117924B2 (en) | 2015-07-06 | 2021-09-14 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JP6882996B2 (ja) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| CA2991214C (en) | 2015-07-06 | 2024-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN105315198A (zh) * | 2015-11-02 | 2016-02-10 | 重庆康乐制药有限公司 | 一种吡非尼酮的晶型及其制备方法 |
| CN105330598B (zh) * | 2015-12-02 | 2017-11-14 | 新发药业有限公司 | 一种吡非尼酮的制备方法 |
| EP3432879B1 (en) * | 2016-03-22 | 2021-01-06 | Mayo Foundation for Medical Education and Research | Using fatty acid synthase inhibitors to treat fibrosis |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| MA44526A (fr) | 2016-04-01 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| EP3439655B1 (en) | 2016-04-08 | 2021-03-03 | Quretech Bio AB | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA45598B1 (fr) | 2016-07-07 | 2021-09-30 | Sage Therapeutics Inc | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| RU2019115113A (ru) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| US11111266B2 (en) | 2016-10-18 | 2021-09-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN106748984A (zh) * | 2016-11-22 | 2017-05-31 | 斯芬克司药物研发（天津）股份有限公司 | 6‑羟甲基‑1‑苯基吡啶‑2‑酮及其制备方法与应用 |
| JP7360171B2 (ja) * | 2017-07-31 | 2023-10-12 | ワシントン・ユニバーシティ | Ｂリンパ球活性の調節及び臓器保護のためのピルフェニドン誘導体 |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
| CN108285431B (zh) * | 2018-03-23 | 2021-04-09 | 北京康蒂尼药业股份有限公司 | 一种吡非尼酮有关物质及其制备方法和用途 |
| WO2022010925A1 (en) * | 2020-07-06 | 2022-01-13 | Puretech Lyt 100, Inc. | Methods of treating diseases and disorders with deupirfenidone |
| SG11202102581YA (en) * | 2018-09-14 | 2021-04-29 | Puretech Lyt 100 Inc | Deuterium-enriched pirfenidone and methods of use thereof |
| WO2021186401A1 (en) * | 2020-03-18 | 2021-09-23 | Puretech Lyt 100, Inc. | Methods of treating lymphedema with deupirfenidone |
| CN114957106B (zh) * | 2022-05-23 | 2024-01-30 | 湖北工程学院 | 药物吡非尼酮的流动相自动合成方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02215719A (ja) | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
| US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| AU707748B2 (en) | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5962478A (en) | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| ES2193921T3 (es) | 1999-12-03 | 2003-11-16 | Pfizer Prod Inc | Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos. |
| EP1134290A3 (en) | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| WO2001092188A1 (en) | 2000-05-29 | 2001-12-06 | Shionogi & Co., Ltd. | Method for labeling with tritium |
| CN1620309A (zh) * | 2001-12-18 | 2005-05-25 | 蒙多生物技术实验室 | 用于结合分子诊断法改进间质性肺疾病的治疗的干扰素γ或甲苯吡啶酮的新型药物组合物 |
| PT1490064E (pt) | 2002-02-14 | 2009-12-28 | Pharmacia Corp | Piridinonas substituídas como moduladores de p38 map-quinase |
| WO2004019863A2 (en) | 2002-08-28 | 2004-03-11 | Intermune, Inc. | Combination therapy for treatment of fibrotic disorders |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| EP1599171A2 (en) | 2003-02-28 | 2005-11-30 | Intermune, Inc. | Combination therapy for treating alphavirus infection and liver fibrosis |
| WO2004105684A2 (en) | 2003-05-16 | 2004-12-09 | Intermune, Inc. | Combination therapy for proliferative disorders |
| WO2005038056A1 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Combination therapy for the treatment of viral diseases |
| WO2005040758A2 (en) | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| JP4072623B2 (ja) | 2004-03-09 | 2008-04-09 | 独立行政法人産業技術総合研究所 | ピリジン−ｎ−オキシド類の製造方法 |
| WO2005110478A2 (en) * | 2004-04-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating fibrotic disorders |
| BRPI0608907A2 (pt) | 2005-05-10 | 2010-02-17 | Itermune Inc | método de modulação de sistema de proteìna cinase ativada por estresse |
| US20080033011A1 (en) | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| US20070203202A1 (en) | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| EP2059241A1 (en) | 2006-09-05 | 2009-05-20 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| US20080287508A1 (en) | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| KR101767849B1 (ko) | 2007-06-20 | 2017-08-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논 |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20110313004A1 (en) | 2008-12-04 | 2011-12-22 | Concert Pharmaceuticals, Inc. | Deuterated pyridinones |
| WO2010085805A1 (en) | 2009-01-26 | 2010-07-29 | Intermune, Inc. | Methods for treating acute myocardial infarctions and associated disorders |
| EP2436670B1 (en) | 2009-05-25 | 2014-04-16 | Central South University | Preparation of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)pyridone compounds and salts thereof and their applications |
| US9018232B2 (en) | 2011-03-08 | 2015-04-28 | Auspex Pharmaceuticals, Inc. | Substituted N-aryl pyridinones |
| CA2835438A1 (en) | 2011-05-25 | 2012-11-29 | Intermune, Inc. | Pirfenidone and anti-fibrotic therapy in selected patients |
| JP2017503839A (ja) | 2014-01-24 | 2017-02-02 | オースペックス ファーマシューティカルズ インコーポレイテッド | 置換ｎ−アリールピリジノン |
| WO2015171345A1 (en) | 2014-04-30 | 2015-11-12 | Auspex Pharmaceuticals, Inc. | N-aryl pyridinones modulators of fibrosis and/or collagen infiltration |
-
2008
- 2008-06-20 KR KR1020167000072A patent/KR101767849B1/ko active Active
- 2008-06-20 WO PCT/US2008/067732 patent/WO2008157786A1/en not_active Ceased
- 2008-06-20 CA CA2691379A patent/CA2691379C/en active Active
- 2008-06-20 US US12/143,484 patent/US8383823B2/en active Active
- 2008-06-20 ES ES08771632T patent/ES2400026T3/es active Active
- 2008-06-20 JP JP2010513457A patent/JP5587184B2/ja active Active
- 2008-06-20 KR KR1020107001341A patent/KR101583737B1/ko active Active
- 2008-06-20 CN CN201510221701.2A patent/CN104892498A/zh active Pending
- 2008-06-20 AU AU2008265595A patent/AU2008265595B2/en active Active
- 2008-06-20 CN CN200880102512A patent/CN101842355A/zh active Pending
- 2008-06-20 NZ NZ599643A patent/NZ599643A/xx unknown
- 2008-06-20 DK DK08771632.0T patent/DK2170828T3/da active
- 2008-06-20 EP EP08771632A patent/EP2170828B1/en active Active
-
2009
- 2009-12-20 IL IL202840A patent/IL202840A/en active IP Right Grant
-
2012
- 2012-10-29 US US13/663,188 patent/US8680123B1/en active Active
-
2013
- 2013-12-18 US US14/132,528 patent/US8969575B2/en active Active
-
2014
- 2014-04-30 US US14/266,048 patent/US9062001B2/en active Active
- 2014-08-08 US US14/455,339 patent/US8969576B2/en active Active
-
2015
- 2015-05-21 US US14/718,993 patent/US9504677B2/en active Active
-
2016
- 2016-02-24 HK HK16102071.0A patent/HK1214251A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008265595A1 (en) | 2008-12-24 |
| HK1214251A1 (zh) | 2016-07-22 |
| US8383823B2 (en) | 2013-02-26 |
| US9062001B2 (en) | 2015-06-23 |
| CA2691379C (en) | 2015-06-09 |
| KR20100050466A (ko) | 2010-05-13 |
| EP2170828A1 (en) | 2010-04-07 |
| DK2170828T3 (da) | 2013-03-04 |
| US20150250777A1 (en) | 2015-09-10 |
| JP5587184B2 (ja) | 2014-09-10 |
| US8969575B2 (en) | 2015-03-03 |
| CN101842355A (zh) | 2010-09-22 |
| CA2691379A1 (en) | 2008-12-24 |
| KR101583737B1 (ko) | 2016-01-11 |
| US8680123B1 (en) | 2014-03-25 |
| EP2170828B1 (en) | 2012-11-21 |
| US20140348928A1 (en) | 2014-11-27 |
| IL202840A0 (en) | 2010-06-30 |
| JP2010530897A (ja) | 2010-09-16 |
| US9504677B2 (en) | 2016-11-29 |
| AU2008265595B2 (en) | 2014-12-04 |
| US20080319026A1 (en) | 2008-12-25 |
| WO2008157786A1 (en) | 2008-12-24 |
| US20140235677A1 (en) | 2014-08-21 |
| US20140107040A1 (en) | 2014-04-17 |
| ES2400026T3 (es) | 2013-04-05 |
| KR20160007684A (ko) | 2016-01-20 |
| IL202840A (en) | 2014-07-31 |
| CN104892498A (zh) | 2015-09-09 |
| KR101767849B1 (ko) | 2017-08-11 |
| US8969576B2 (en) | 2015-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ599643A (en) | Substituted N-aryl pyridinones as fibrotic inhibitors | |
| ZA200407234B (en) | New inhibitors of histone deacetylase. | |
| HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
| HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
| IL279460B2 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| HRP20201946T1 (hr) | Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutski sastavi, postupci liječenja, i postupak za dobivanje modulatora | |
| HRP20221195T1 (hr) | Spojevi koji ciljaju psma i njihova uporaba | |
| RU97114938A (ru) | Замещенные гетероциклические соединения, способ получения указанных соединений и содержащие их фармацевтические композиции | |
| BR9509212A (pt) | Composto composição farmacêutica método de inibição de prostaglandina H sintase em um mamífero método de tratamento de uma doença inflamatória em um mamífero e método de tratamento de pirese em um mamífero | |
| MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
| DK0532527T3 (da) | 3-amino-2-arylquinuclidiner, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse | |
| MXPA04004464A (es) | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. | |
| RS54509B1 (en) | BENZYLAMINE DERIVATIVES AS Plasma KALIKREIN INHIBITORS | |
| BR0312322A (pt) | Compostos, composições, métodos para o tratamento da dor em um animal, da incontinência urinária em um animal, de uma úlcera em um animal, de sìndrome de intestino irritável em um animal, da doença inflamatória do intestino em um animal, métodos para a inibição da função de vr1 em uma célula, kits e métodos para a preparação de uma composição | |
| JP2004525174A5 (enExample) | ||
| CN111836814A (zh) | 稠环化合物、其制备方法及用途 | |
| NZ594671A (en) | Compositions and methods for inhibiting the agglomeration of hydrates in a process | |
| ATE550337T1 (de) | Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kappa-b-aktivität und deren verwendung | |
| DE69928567D1 (de) | Biodegradierbare polyphosphoester-zusammensetzungen zur behandlung von ovarialkrebs | |
| WO2008043911A3 (fr) | Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant | |
| Harford et al. | New avenues in the directed deprotometallation of aromatics: recent advances in directed cupration | |
| EA200970705A1 (ru) | Новые фармацевтические композиции | |
| SG11201804636YA (en) | Composition for post chemical-mechanical-polishing cleaning | |
| JP2012516349A5 (enExample) | ||
| PH12012500775A1 (en) | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 JUN 2015 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20140624 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2016 BY COMPUTER PACKAGES INC Effective date: 20150602 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2017 BY DENNEMEYER + CO Effective date: 20160520 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2018 BY DENNEMEYER + CO. Effective date: 20170522 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2019 BY DENNEMEYER + CO Effective date: 20180526 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2020 BY DENNEMEYER + CO. Effective date: 20190522 |
|
| ASS | Change of ownership |
Owner name: PURETECH LYT 100, INC., US Effective date: 20191121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2021 BY DENNEMEYER + CO. Effective date: 20200608 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2022 BY DENNEMEYER+CO. Effective date: 20210607 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2023 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20220613 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2024 BY COMPUTER PACKAGES INC Effective date: 20230530 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2025 BY COMPUTER PACKAGES INC Effective date: 20240530 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2026 BY COMPUTER PACKAGES INC Effective date: 20250530 |